Sawai Pharmaceutical Co., Ltd.
FY2020 Financial Results for the 1st Half
November 11, 2020
FY2020 Financial Results for the 1st Half
Overview
Operating Income Analysis
Sales by Channel, Japan (Unconsolidated)
Sales by Product Launch Year, Japan
US Sales Analysis
FY2020 Forecasts, consolidated
Current Status of The U.S. Business
U.S. Market Trends
COVID-19 Business Impacts
Acute Pharmaceutical Performance
FDA ANDA Activity
Generic Price Trends
USL Strategy
Company Strategy
Brand Acquisition Strategic Focus
Generic Pipeline Launch by Year
Project Keystone
Zembrace & Tosymra Performance September YTD FY2020
Zembrace & Tosymra Performance
Financial Performance of US Business September YTD FY2020
Overview of the Financial Results
Important Story Lines